This product is used in three doses and induces maximum immunity 42 days after the first application. Patients receive the second dose on day 14 and the third one on day 28.
In its clinical trials, this Cuban vaccine demonstrated an efficacy of 92.28 percent, which is the fourth highest worldwide, as explained by BioCubaFarma representative Pedro Almenarez.
Nor has the use of Abdala implied adverse reactions in patients. So far, over 80 percent of people immunized with this product have not needed to use medication or receive any post-vaccination therapy.
1/ Ahead of the announcement that its Abdala vaccine has an efficacy rate of 92.28%, Cuba ���� committed to help vaccinate the world with open licensing to Summit partners and beyond. pic.twitter.com/v9gpmHpmAt
Around 12 million Abdala vaccines will arrive in Venezuela between July and October to be used in a health campaign whose goal is to immunize 70 percent of the population in the short term.
Over the past month, President Nicolas Maduro has denounced to the international community that the U.S. arbitrary sanctions blocked money to pay for 5 million COVID-19 vaccines his nation purchased through the COVAX facility.
Since February, this South American country has received 3.5 million Russian and Chinese vaccines to immunize a population of over 28 million.
Despite an intensified US blockade, #Cuba provides the world with two COVID-19 vaccines.
Soberana 02, with 62% efficacy after two doses—likely to rise after the Soberana Plus trial results are known.